Regeneron: adjusted EPS up 13% in Q2

(CercleFinance.com) - Regeneron reports Q2 sales of $3,547 million, up 12% on the same period a year earlier.


The US biotech company reported adjusted net income (non-GAAP) of $1,351 million, up 14%, and adjusted EPS of $11.56, up 13%.

Our second-quarter financial results reflect the continued momentum of our business, illustrated by double-digit growth in sales and earnings", said Christopher Fenimore, Regeneron's Senior Vice President Finance and CFO.

Copyright (c) 2024 CercleFinance.com. All rights reserved.